Abstract-Because of the presence of the blood-brain barrier, brain renin-angiotensin system activity should depend on local (pro)renin synthesis. Indeed, an intracellular form of renin has been described in the brain, but whether it displays angiotensin (Ang) I-generating activity (AGA) is unknown. Here, we quantified brain (pro)renin, before and after buffer perfusion of the brain, in wild-type mice, renin knockout mice, deoxycorticosterone acetate salt-treated mice, and Ang II-infused mice. Brain regions were homogenized and incubated with excess angiotensinogen to detect AGA, before and after prorenin activation, using a renin inhibitor to correct for nonrenin-mediated AGA. Renin-dependent AGA was readily detectable in brain regions, the highest AGA being present in brain stem (>thalamus=cerebellum=striatum= midbrain>hippocampus=cortex). Brain AGA increased marginally after prorenin activation, suggesting that brain prorenin is low. Buffer perfusion reduced AGA in all brain areas by >60%. Plasma renin (per mL) was 40× to 800× higher than brain renin (per gram 
S
ince the discovery of renin in the brain nearly 50 years ago, 1 numerous studies have proposed that a so-called brain renin-angiotensin system (RAS) exists. Given the presence of the blood-brain barrier, brain RAS activity should depend on the local synthesis of renin or prorenin (together denoted as (pro)renin) in the brain rather than uptake from blood. In support of this concept, an intracellular, nonsecreted form of renin (icREN) has been shown to occur exclusively in the brain. This renin isoform is derived from an alternative transcript of the renin gene, lacking the signal peptide and part of the prosegment. 2, 3 To what degree this truncated prorenin truly generates angiotensin (Ang) I remains elusive. Lee-Kirsch et al 2 detected low Ang I-generating activity (AGA) levels in cell lysates of AtT20 cells transfected with icREN during incubation with excess angiotensinogen, but failed to demonstrate to what degree this AGA was renin-mediated (eg, by making use of a renin inhibitor). Peters et al 4 showed increased AGA in cardiac homogenates of transgenic rats overexpressing icREN and were able to block this with the renin inhibitor CH732. Yet, unexpectedly, the AGA increase was observed only after prosegment removal with trypsin, in disagreement with the fact that truncated prorenin does not require prosegment removal to display activity. 5 Moreover, icREN overexpression in the heart, if anything, resulted in effects that were unrelated to angiotensin formation. 6 Deoxycorticosterone acetate (DOCA) salt treatment is widely believed to stimulate brain RAS activity. Confusingly, it lowers icREN expression, but increases the expression of the classical, secreted form of renin in brain tissue (sREN), 7 possibly because icREN, via an unknown mechanism, inhibits sREN expression. 8 Li et al 9, 10 proposed that DOCA salt selectively increases brain prorenin, which, in the absence of a prosegment-cleaving enzyme in the brain, requires interaction with the (pro)renin receptor to allow Ang I generation locally. The underlying assumption of this concept is that prorenin binding to the (pro)renin receptor results in a conformational change in the prorenin molecule, allowing it to display enzymatic activity without prosegment cleavage. 11 Yet, the low (nanomolar) affinity of the (pro)renin receptor implies that high prorenin levels are required for receptor binding, 11 for which there currently is no evidence. 10 Given these uncertainties, in the present study, we set out to re-evaluate the occurrence of (pro)renin in the brain. We quantified brain (pro)renin in a wide variety of brain regions, derived from control mice, mice exposed to DOCA salt or Ang II, and renin-deficient mice. Under all conditions, a comparison was made with plasma (pro)renin, and the renin inhibitor aliskiren was applied in the assay to evaluate whether AGA was truly renin mediated. Mice were studied given the fact that their (pro)renin levels are several orders of magnitude higher than those in humans or rats, thereby, facilitating the detection of renin-dependent AGA, even in areas with low (pro)renin levels. To obtain a more complete understanding of the brain RAS, we also quantified brain angiotensinogen, and we studied the changes in brain angiotensin generation making use of brain stem tissue obtained from control spontaneously hypertensive rats (SHR) and SHR treated with the Ang II type 1 (AT 1 ) receptor blocker olmesartan or the angiotensinconverting enzyme inhibitor lisinopril for 4 weeks.
Methods

Mouse and Rat Studies
Renin, prorenin, and angiotensinogen were measured in plasma and brain regions (cerebellum, brain stem, cortex, hippocampus, midbrain, striatum, and thalamus) obtained from wild-type mice, mice treated with DOCA salt or Ang II, and renin-deficient mice (Ren1c −/− ), either without and with transcardial perfusion with PBS to wash away blood from the brain vasculature. Renin expression in brain tissue was also explored by using Ingenuity Pathway Analysis, and angiotensinogen synthesis was additionally studied in rat primary cortical astrocytes. Angiotensins were measured in plasma and brain stem tissue obtained from SHR treated with vehicle, lisinopril or olmesartan. For further details, see the Methods section in the online-only Data Supplement.
Statistical Analysis
Data are expressed as mean±SEM. Univariate linear associations between plasma and brain renin levels were assessed by calculation of Pearson's coefficient of correlation. Differences between groups were evaluated by Student's t test or analysis of variance and corrected for multiple testing by post hoc Bonferroni analysis when needed. P<0.05 was considered significant.
Results
Aliskiren Inhibits AGA in the Mouse Brain
Aliskiren identically inhibited AGA in mouse plasma (n=2), mouse kidney homogenate (n=2), and mouse brain homogenate (n=3; Figure 1 ). Its half maximal inhibitory concentration was in the nanomolar range, as has been reported before for mouse renin. 12, 13 These data suggest that AGA in mouse brain homogenates is caused by renin. All subsequent AGA measurements were performed both in the absence and presence of 10 μmol/L aliskiren to correct for nonrenin (ie, nonaliskiren-inhibitable) AGA.
Buffer Perfusion Reduces Mouse Brain Renin by >60%
Renin-dependent (ie, aliskiren-inhibitable) AGA was readily detectable in brain regions, the highest AGA being present in brain stem (>thalamus=cerebellum=striatum=midbrain> hippocampus=cortex; Figure 2 ; n=5/group). AGA increased in each individual brain region after prorenin activation, but only when analyzing all brain regions together by multivariate analysis of variance did this increase reach significance (P<0.05). Applying the prorenin activation procedure to 3 mouse brain homogenates (cortex, midbrain, and brain stem, respectively) to which recombinant human prorenin had been added yielded values in a renin immunoradiometric assay (211±12 pg/mL) that were similar to those when activating the same amount of recombinant human prorenin in buffer with aliskiren 14 (169±6 pg/mL). This confirms that our prorenin activation procedure was appropriate. PBS perfusion of the mouse brain reduced AGA in all brain areas by >60% (Figure 2 ; P<0.01) and diminished the percentage of AGA that could be blocked by aliskiren (Table S2 in the online-only Data Supplement). These data suggest that blood removal predominantly washes away renin, but not nonrenin enzymes that are also capable of reacting with angiotensinogen. Plasma renin (expressed per milliliter of plasma) was 40× to 800× higher than brain renin (expressed per gram of tissue) and, as expected, identical in mice that were exposed to buffer perfusion. Plasma prorenin levels were of the same order of magnitude as plasma renin levels, as demonstrated earlier in mice. AGA were present in brain stem (1 out of 4), midbrain (3 out of 4), and cortex (2 out of 4) after prorenin activation in the Ren1c −/− mice. Because this cannot represent prorenin, these data imply that our prorenin activation procedure occasionally activated a renin-like enzyme, capable of reacting with angiotensinogen, the activity of which can be blocked by 10 μmol/L aliskiren.
Renin Expression in the Brain
Renin (secreted+intracellular), sREN, or icREN mRNA expression levels were undetectable in all brain regions in wild-type, DOCA salt-treated, and Ang II-infused mice. Primer specificity for renin (secreted+intracellular) and sREN was validated by measuring renal renin expression in Ren1c −/− mice ( Figure S1B ). In the Ingenuity Pathway Analysis tissue expression data sets, renin expression was found in cerebellum, hypothalamus, and pituitary, but only in 3 out of 9 different data sets examined (data not shown).
Despite Angiotensinogen Expression, Angiotensinogen Protein Is Undetectable in Mouse Brain and Rat Astrocytes
Mouse plasma contained detectable levels of angiotensinogen (28±5 pmol/mL). Angiotensinogen mRNA expression was observed in different brain regions ( Figure 5 ), at C t values of 23 (cerebellum), 22 (thalamus), 25 (hippocampus), and 27 (striatum) versus ≈18 in the liver. Brain expression levels changed inconsistently after DOCA salt, Ang II, and renin deficiency: an increase was observed in the thalamus after DOCA salt (P<0.05), while decreases occurred in the cerebellum after DOCA salt (P<0.05) and in the hippocampus after Ang II (P<0.05). Yet, angiotensinogen protein was undetectable (<1 pmol/g) in mouse cortex and brain stem (n=4 of each). Angiotensinogen was also undetectable in the medium of cultured rat astrocytes (<0.3 pmol/mL), cultured for 24, 48, 72, or 96 hours (n=4 for each condition), or the accompanying cell lysates (<0.3 pmol/mg protein).
Angiotensins in the SHR Brain With and Without RAS Blockade
Ang I, Ang-(1-7), and Ang-(2-8) were below detection limit in brain tissue of untreated SHR (n=6), while Ang II could be detected in the rat brain at levels corresponding with ≈25% of the Ang II levels in blood plasma (Table S3 ; Figure 6 ). Ang I and Ang-(2-8), but not Ang-(1-7), were detectable in plasma in untreated SHR. Brain Ang-(1-7) and Ang-(2-8) remained undetectable after olmesartan (n=6) or lisinopril (n=4), while Ang I became detectable in the rat brain after both types of RAS blockade (P<0.001 for both). Because plasma Ang I increased ≈20-fold after olmesartan and lisinopril (P<0.001 for both), it could be calculated that during both types of RAS blockade, brain Ang I levels corresponded with ≈1% of the Ang I levels in plasma. Olmesartan increased brain Ang II ≈5-fold (P<0.001) and plasma Ang II ≈25-fold (P<0.001), so that after AT 1 receptor blockade, the brain/plasma ratio of Ang II decreased by ≈80% (P<0.05). Lisinopril decreased plasma Ang II by >90% (P<0.001) and diminished brain Ang II to undetectable levels (P<0.001). Lisinopril also decreased plasma Ang-(2-8) to undetectable levels and greatly increased plasma Ang-(1-7), while olmesartan increased both plasma Ang-(2-8) and plasma Ang-(1-7). Taken together, given that brain Ang I levels correspond with ≈1% of the circulating Ang I levels, 10 μL plasma per gram brain tissue is sufficient to explain the entire brain Ang I content. Brain Ang II levels, relative to plasma Ang II levels, are higher, suggesting either local synthesis or an active uptake mechanism. The massive decrease in the Ang II brain/plasma ratio after olmesartan supports the latter.
Discussion
The present study confirms that renin-dependent AGA can be detected in virtually every region of the mouse brain. Yet, as compared with plasma, brain renin levels were This volume mimics the amount of blood plasma in various brain regions determined with tritiated inulin or Evans blue dye. 16, 17 Moreover, perfusing the brain with PBS prior to the collection of the various regions reduced brain renin uniformly by >60%. Had local renin synthesis occurred in one or more specific brain regions, the washout percentage should have been much lower in these regions, similar to the fact that in the kidney, one cannot wash away stored renin, 18, 19 while this does happen in nonrenin producing organs like the heart. 20 Furthermore, DOCA salt, like Ang II, reduced circulating renin and, contrary to our expectations, did not increase brain prorenin. In fact, if anything, both DOCA salt and Ang II lowered brain renin in parallel with plasma renin. Aliskiren-inhibitable AGA was entirely absent in the brain of Ren1c −/− mice, supporting the validity of our brain renin measurement. Taken together, our data do not support the presence of kidney-independent (pro)renin synthesis in the brain, nor the concept that this occurs particularly in the DOCA salt model. In fact, brain renin levels are so low that the accumulation of renin at brain tissue sites outside the blood compartment seems unlikely. This greatly differs from other organs (eg, the heart), where renin diffuses freely into the interstitium or binds to a receptor, thereby reaching tissue levels that are, on a gram basis, at least as high as the renin levels in blood plasma (on an mL basis). [20] [21] [22] Clearly, the presence of the blood-brain barrier prevents such distribution.
Prorenin activation resulted in modest AGA increases in all brain regions, and significance for this increase was only obtained by analyzing all regions together. Applying recombinant human prorenin to brain homogenates prior to the prorenin activation procedure (on the basis of acid activation 22 ) confirmed that this procedure resulted in complete prorenin activation. However, small rises in aliskiren-inhibitable AGA were also observed in brain homogenates from Ren1c −/− mice after their exposure to acid. Because Ren1c −/− mouse brain tissue cannot contain prorenin, this implies that the brain contains a nonrenin proenzyme, which is activated by acid exposure and which is capable of cleaving Ang I from angiotensinogen in an aliskiren-inhibitable manner. A possible candidate is procathepsin D. Indeed, renin inhibitors, at high micromolar concentrations, do inhibit cathepsin D. 23 Our difficulty to demonstrate prorenin in the brain is reminiscent of earlier studies in organs not synthesizing prorenin themselves, like the heart. 22 Obviously, blood plasma contains prorenin, and thus, some prorenin should be detected in the blood-containing homogenates derived from such tissues. Yet only under conditions where circulating prorenin levels were greatly elevated, like in heart failure in humans, did we reliably detect prorenin in cardiac tissue. 24 In mice, in contrast to humans, circulating prorenin levels are relatively low (versus renin), making it even more difficult to show a rise in AGA on top of already low renin-mediated AGA. A further complicating factor is that tissue homogenization per se may result in (partial) prorenin activation. In summary, given the presence of prorenin in blood plasma, brain homogenates should minimally contain the amount of prorenin present in a few microliter of blood. The rises in AGA after prorenin activation are consistent with this view, but should still be interpreted with caution given the fact that nonrenin enzymes also came into play after acid activation. Brain-selective prorenin rises, for example, after DOCA salt, were not observed. This implies that prorenin-(pro) renin receptor interaction is unlikely to occur in the mouse brain, particularly after DOCA salt (which lowers brain (pro) renin), although it may obviously occur after intracerebroventricular infusion of pharmacological prorenin doses into the brain. 10 Most, if not all, studies on brain renin relied on the detection of renin mRNA in the brain, either under normal conditions or after deleting/overexpressing sREN or icREN. Deleting sREN in neurons or glia did not affect blood pressure, heart rate, water intake, or metabolic rate, 25 while preservation of icREN did not compensate for the consequences of whole-body sREN deficiency (hypotension, renal defects, and lethality).
26 Surprisingly, brain-selective deletion of icREN even caused neurogenic hypertension, possibly because icREN inhibits sREN. 8 These data seem to argue against icREN as an Ang I-generating enzyme. Yet, overexpressing either human icREN or sREN in astrocytes, if combined with human angiotensinogen, resulted in Ang II-dependent hypertension and an increase in drinking volume. 27 Because icREN under the latter conditions was not detectable in cerebrospinal fluid, it was concluded that this phenomenon involved intracellular Ang II formation. We attempted to detect renin mRNA, using either specific assays for sREN or icREN or a nonspecific assay that detects both sREN and icREN. Under no condition were we able to show renin (secreted+intracellular), sREN, or icREN gene expression in any of the different regions of the brain: the expression level was below the detection threshold of the reverse transcriptase polymerase chain reaction assay, even with the use of the highly sensitive Taqman probes. The specificity of our renin primers was validated by making use of the kidneys of Ren1c −/− mice. Of course, poor renin expression in the brain has been noted before. [28] [29] [30] Because of the technical limitations inherent in any reverse transcriptase polymerase chain reaction assay, we could not load >100 ng of total RNA. Our results, therefore, indicate that if renin is expressed in the brain, its expression is >2 18 -fold lower than that in the kidney (no signal after 40 cycles, with renin detection in the kidney at C t =22). The Ingenuity Pathway Analysis expression data sets confirm this view. Yet, Kubo et al 31 observed a blood pressure drop after intraventricular renin antisense injection in SHR. In their hands only 1 of 3 tested antisense oligonucleotides acted hypotensive, and this response was accompanied by a 20% drop in renin mRNA (detected after 45 cycles of reverse transcriptase polymerase chain reaction). These authors did not measure renin levels in brain or plasma and were unable to rule out antisense leakage to the kidney. Therefore, these data cannot be taken as definitive proof for the existence of an independent brain RAS.
The mouse RAS differs from the human RAS, in that the circulating renin levels in mice are ≤1000-fold higher (on a nanogram Ang I/mL hour basis) than in humans. As a consequence, circulating angiotensinogen levels in mice are far below K m range, as confirmed in the present study. Nevertheless, despite these differences, mouse angiotensin levels in blood and tissue are comparable to those in humans, rats, and pigs. [32] [33] [34] [35] We attempted to measure angiotensinogen in the mouse brain, both at the mRNA and protein level. Although we did observe angiotensinogen mRNA expression in different regions of the brain, in full agreement with previous work, 36, 37 expression was ≤500-fold lower than in the liver. Under no condition were we able to detect angiotensinogen protein in the brain. Given the detection limit of our assay (1 pmol/g), this implies that brain angiotensinogen, if present, occurs at levels (per gram of tissue) that are <3% of the levels in plasma (per milliliter of plasma). Such low levels have been reported before in the rat brain, as well as in human and rat cerebrospinal fluid, 16, [38] [39] [40] and thus, our data entirely agree with the literature. Clearly, mice, given their low angiotensinogen levels, are not the optimal species to study brain angiotensinogen. As astrocytes are assumed to be the source of brain angiotensinogen, 41, 42 we additionally studied angiotensinogen synthesis by rat primary cortical astrocytes, but again failed to detect any angiotensinogen. Nevertheless, data from Schink et al. 40 do support the functional presence of angiotensinogen in the rat brain. These authors artificially elevated renin in the brain by either intracerebroventricular renin infusion (in Sprague-Dawley rats) or by making use of transgenic hypertensive rats overexpressing mouse Ren2. The responses to both approaches (drinking and blood pressure reduction, respectively) were greatly diminished after lowering brain angiotensinogen by brain-selective expression of an antisense RNA against angiotensinogen mRNA.
Finally, given our observation that brain renin is confined to the plasma compartment, while brain angiotensinogen is extremely low (if not also confined to the plasma compartment), an urging question is what degree local angiotensin generation truly occurs in the brain. We, therefore, collected brain stem tissue (ie, the brain region with the highest renin level) from SHR under control conditions and during RAS blockade with olmesartan or lisinopril. Rats rather than mice were used here because at identical angiotensin levels in both species, the larger rat brain stem would allow a more reliable quantification of angiotensins. Without treatment, brain Ang I was undetectable, while Ang II occurred at levels that were ≈25% of the levels in plasma (per gram tissue weight). This contrasts with other organs where Ang II is usually much higher than in plasma, while Ang I is easily detectable. [43] [44] [45] [46] RAS blockade induced the usual rise in Ang I levels in plasma, and now brain Ang I became detectable, however, at only 1% (v/v) of its plasma levels. It seems reasonable to assume that also in the untreated animals, brain Ang I levels were in the 1% range of plasma Ang I and, therefore, too low to be detected with our assays. If so, this implies that under all conditions, brain Ang I at most represented the amount of Ang I that is inherently present in brain tissue because it contains a small amount (≈1%) of blood. 16 Lisinopril decreased brain Ang II to undetectable levels, while olmesartan reduced the brain/plasma Ang II ratio by >80%. The latter finding suggests that, normally, circulating Ang II accumulates in brain tissue via binding to AT 1 receptors. Such uptake occurs in multiple organs 47 and facilitates the intracellular accumulation of Ang II. 48 Without receptors (ie, in AT receptor-deficient mice), tissue Ang II levels drop dramatically, 49 suggesting that tissue Ang II levels do not originate intracellularly. If Ang II binding to AT 1 receptors is the only source of Ang II in the brain, one would expect angiotensin metabolites that do not (or only with low affinity) bind to this receptor to be undetectable in the brain. This is indeed what we observed for both Ang-(2-8) and Ang-(1-7). An olmesartan-induced reduction in brain Ang II levels was also observed in Dahl-sensitive hypertensive rats, albeit in the absence of an effect on blood pressure. 50 Clearly, therefore, the changes observed in brain Ang II are blood pressure independent.
Perspectives
The absence of renin-dependent AGA in the brain outside the blood compartment implies that angiotensin generation in the brain, if occurring, does not involve renin. Brain prorenin levels, if anything, were even lower than brain renin levels and, therefore, like renin, at most represented the amount of prorenin expected in brain tissue based on its blood content. Selective brain prorenin upregulation, for example, after DOCA salt, could not be observed, arguing against the concept that DOCA salt-induced neurogenic hypertension involves prorenin-(pro)renin receptor interaction. Finally, the absence of Ang I in brain tissue outside the blood compartment (which contrasts sharply with the presence of Ang I in every other organ of the body) strongly suggests that there is no local Ang I generation in the brain. Apparently, therefore, nonrenin enzymes do not compensate for the absence of renin, assuming at least that brain angiotensinogen levels are of sufficient magnitude to allow independent Ang I generation at all. Only ex vivo, after prohormone-activating procedures, did we occasionally obtain evidence for a modest contribution of such nonrenin enzymes, but the in vivo relevance of these findings is questionable. Brain Ang II, therefore, seems to originate in the blood compartment. Of course, circulating Ang II will bind to brain AT receptors that are outside the blood-brain barrier (eg, in the circumventricular organ). Yet, it may also gain access to brain areas behind this barrier, for example, under conditions where blood-brain barrier permeability is compromised, like in (DOCA salt) hypertension. 51, 52 In fact, Ang II itself may be responsible for disturbing the blood-brain barrier, thus, facilitating its own access to critical brain areas like the hypothalamus and brain stem. From this perspective, the brain RAS in reality represents circulating Ang II that accumulates in brain nuclei, possibly after it has (partially) broken down the blood-brain barrier. This Ang II subsequently activates sympatho-neurohumoral outflow, for instance, by upregulating reactive oxygen species. 52, 53 This is entirely different from other organs like heart, kidney, and vascular wall, where renin and angiotensinogen diffuse freely into the interstitial space, allowing local production of Ang I to occur. 20, 54, 55 Blocking AT 1 receptors or enhancing Ang II degradation (eg, by angiotensinconverting enzyme 2) will prevent the effects of circulating Ang II in the brain, thereby explaining the success of intracerebroventricular application of losartan or brain-selective angiotensin-converting enzyme 2 overexpression in DOCA salt hypertension. 
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